Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

NPS+ Non-Small Cell Lung Cancer [Orals] (EU5) 2019

Product Code:
s_596201346
Publication Date:
February 2019
Format:
PDF
Price:
$2,785

Unique product-level analysis for improving brand health and clinician satisfaction in the EU5

  • How loyal are clinicians to specific brands?
  • How do leading clinicians rate key oral NSCLC brands?
  • What brand messages resonate with Promoters, Passives and Detractors?
  • What is the market share of leading brands among Promoters and Detractors?

Clinicians treating NSCLC have a number of effective therapy options, but not all make the same choices. What drives clinician prescribing and decision making and why are some more loyal to certain brands than others?

This and other key questions are answered in this insightful February 2019 Net Promoter Score®1 (NPS) analysis of 8 leading oral NSCLC brands. Based on the results of an in depth survey of 150 EU5-based medical oncologists, NPS+ (EU5) Non-Small Cell Lung Cancer [Orals] identifies the drivers that build clinician satisfaction and brand loyalty.

Buy Now

Buy and Download this report

Leading brands covered in this report

  • Alecensa (alectinib; Roche)
  • Giotrif (afatinib; Boehringer Ingelheim)
  • Iressa (gefitinib; AstraZeneca)
  • Mekinist/Tafinlar (trametinib/dabrafenib; Novartis)
  • Tagrisso (osimertinib; AstraZeneca)
  • Tarceva (erlotinib; Roche)
  • Xalkori (crizotinib; Pfizer)
  • Zykadia (ceritinib; Novartis)

This NPS analysis answers important brand questions

  • What underpins the high-ranking NPS scores for Tagrisso, Alecensa and Xalkori?
  • How brand-loyal are clinicians and which brands are at risk of clinicians switching to a competitor?
  • Overall, how satisfied are clinicians with available brands and what new opportunities exist?
  • What is the market share of Mekinist/Tafinlar, Zykadia and Tarceva among promoters and detractors?
  • Cost effective? Convenient administration? Slows disease progression? What messages are resonating with Detractors, Passives and Promoters for Alecensa, Giotrif, Iressa and Zykadia?

FirstView NPS+ takes you deeper than the standard NPS analysis

Since its introduction in 2003, the Net Promoter Score system has become established as a key metric for assessing user satisfaction and loyalty to brands. But while NPS helps you measure overall brand health, it doesn't tell you how to improve it. NPS+ adds much needed detail and gives you deep insights into:

  • The value of specific brands to Promoters
  • Messages Promoters, Passives and Detractors associate with brands
  • Brands that are at risk of losing out to competitors
  • Brand loyalty, and what drives it

Exclusive to FirstView and not available elsewhere, NPS+ does more than measure your brand’s overall health—it shows you what drives brand satisfaction so you can take action to improve physician engagement and use.

About the Medical Oncologists surveyed

This detailed analysis—based on a survey of 150 EU5 medical oncologists who play an active role in writing prescriptions for their NSCLC patients—establishes which therapies they use and the clinical characteristics that influence their choices.

This report gives you...

  • 23 clear, easy to read charts that provide at-a-glance understanding of the survey findings
  • Practical data to understand how medical oncologists rank leading therapies
  • Actionable data for addressing negative brand perceptions

What are Net Promoter Scores?

NPS measures overall brand satisfaction and loyalty by asking one simple question:

"How likely are you to recommend this brand to a colleague?"

Responses, given on a scale of 0 to 10, are used to classify doctors into 3 categories:

  • Detractors are those who answer 0 - 6
  • Passives are those who answer 7 - 8
  • Promoters are those who answer 9 - 10

Why FirstView has an edge in pharmaceutical market research

FirstView research draws on LiMA (Leaders in Medicine Atlas), the world's largest directory of 3.5 million vetted and verified physicians. This proprietary physician research platform uses advanced big data capture, processing and analytics powered by AI and machine learning to ensure the most robust samples are used for every FirstView survey.

Buy Now

Buy and Download this report

Other NSCLC [ORALS] reports available

NPS+ Non-Small Cell Lung Cancer [Orals] US

Medical Affairs Reputations US: Non-Small Cell Lung Cancer [Orals]

Medical Affairs Reputations Europe: Non-Small Cell Lung Cancer [Orals]

Market Access Impact US: Non-Small Cell Lung Cancer [Orals]

Market Access Impact Europe: Non-Small Cell Lung Cancer [Orals]

To learn about our cost effective NSCLC [Orals] intelligence package of all reports, please contact us at info@fwreports.com

1NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved